‹ ›
MYP_008631
← PREVIOUS NEXT → BACK
Basic Information
Peptide 3
Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2
Antiviral ▸ Anti-Herpesvirus ▸ Anti-HCMV
Antiviral ▸ Antiviral mechanism ▸ Viral entry inhibition
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Cytotoxic
Standard
8 amino acids
C32H55N9O10
Standard
Sequence
GGVLVQPG
Physicochemical Analysis
725.83 Da
5.53
-0.24
-0.44
-0.0300
0.74
0.25
0.49
48.25
121.25
0.0000
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
301.32
-3.18
9.0
10.0
21.0
51.0
1.0
8.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0376217 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acylation
Amidation
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
cytomegalovirus (HCMV) Davis strain:inhibition of virus activity in human embryonic lung (HEL) cells
20 μM
EC50
PMID34502335 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34502335/
RECORD: Rec_0383406 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Pivaloylation
Methyl amidation
Pivaloylation; Methyl amidation
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Entry inhibition
SARS-CoV-2 UC-1074 | Vero cells
20 μM
EC50
Mammalian: 30 h; Yeast: >20 h; E. coli: >10 h
PaperPeptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation. | Di Micco S, Musella S, Sala M, Scala MC, Andrei G, Snoeck R, Bifulco G, Campiglia P, Fasano A. | Int J Mol Sci. 2021 Aug 30;22(17):9427. | DOI:10.3390/ijms22179427 | PMID:34502335 PMID34502335 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34502335/
RECORD: Rec_0384015 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acylation
Methyl amidation
Acylation; Methyl amidation
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Entry inhibition
SARS-CoV-2 UC-1074 | Vero cells
20 μM
EC50
Mammalian: 30 h; Yeast: >20 h; E. coli: >10 h
PaperPeptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation. | Di Micco S, Musella S, Sala M, Scala MC, Andrei G, Snoeck R, Bifulco G, Campiglia P, Fasano A. | Int J Mol Sci. 2021 Aug 30;22(17):9427. | DOI:10.3390/ijms22179427 | PMID:34502335 PMID34502335 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34502335/
RECORD: Rec_0394739 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acylation
Amidation
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
cytomegalovirus (HCMV) AD-169 Strain:inhibition of virus activity in human embryonic lung (HEL) cells
20 μM
EC50
PMID34502335 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34502335/
RECORD: Rec_0396234 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acylation
Amidation
Acylation
Bio-Activity Profile
Antiviral Entry inhibition
varicella-zoster virus (VZV) TK-VZV Strain 07-1
48.42 μM
EC50
Mammalian: 30 h; Yeast: >20 h; E. coli: >10 h
PaperPeptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation. | Di Micco S, Musella S, Sala M, Scala MC, Andrei G, Snoeck R, Bifulco G, Campiglia P, Fasano A. | Int J Mol Sci. 2021 Aug 30;22(17):9427. | DOI:10.3390/ijms22179427 | PMID:34502335 PMID34502335 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34502335/
FIRST PREV 1 ... 8 9 10 11 NEXT LAST
Showing 5 records on this page · Page 10 of 11